Eli Lilly and Company announced recently that the US Food and Drug Administration approved Cyramza in combination with the chemotherapeutic drug paclitaxel as a treatment for people with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy. This grants Cyramza two FDA approvals, following on the April approval of Cyramza as a single agent for the same condition.